Genentech, Inc.
NEWS
This deal is an expansion of an existing discovery collaboration. Immunocore will head the first-in-human clinical trial of the drug alone and in combination with Genentech’s checkpoint inhibitor Tecentriq (atezolizumab).
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Rob Dunn, a professor of applied ecology at North Carolina State University in Raleigh recently wrote a book, Never Home Alone. In this book, he describes how millions of microorganisms, bacteria, fungi, viruses, parasites and insects live in your home—and in and on your body.
Biopharma companies name new members of their leadership teams. Who made big moves this week?
According to the American Cancer Society, almost 601,000 people in the U.S. died of cancer in 2017. The two most common types of cancer are lung cancer and breast cancer, followed by colorectal cancer, prostate cancer and stomach cancer.
It was 36 years ago when Food and Drug Administration (FDA) approved Eli Lilly and Company’s Humulin, the first human Recombinant insulin for diabetes treatment.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
Four former Genentech employees have been indicted by a federal grand jury for the alleged theft of company trade secrets in order to help a company set up in Taiwan develop drugs similar to those made by the Roche subsidiary.
JOBS
IN THE PRESS